Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement

被引:0
|
作者
Bor-Sheng Ko
Cheng-Shyong Chang
Ming-Chih Chang
Tsai Yun Chen
Tzeon-Jye Chiou
Chang-Fang Chiu
Wen-Li Huang
Woei-Yau Kao
Yii-Jenq Lan
Shen-Fung Lin
Tran-Der Tan
Jih-Luh Tang
Cheng-Hwai Tzeng
Po-Nan Wang
Su-Pen Yet
Hwei-Fang Tien
机构
[1] National Taiwan University Hospital,Division of Hematology, Department of Internal Medicine
[2] National Health Research Institute,Institute of Systemic and Cellular Medicine
[3] Changhua Christian Hospital,Department of Internal Medicine
[4] Mackay Memorial Hospital,Department of Hematology
[5] Mackay Medical College,Oncology
[6] College of Medicine,Section of Hematology/Oncology, Department of Internal Medicine
[7] National Cheng Kung University,Division of Transfusion Medicine, Department of Medicine
[8] Taipei Veterans General Hospital,Cancer Center
[9] National Yang-Ming University School of Medicine,Department of Medicine
[10] China Medical University Hospital,Division of Hematology/Oncology
[11] School of Medicine,Division of Hematology
[12] China Medical University,Oncology, Department of Internal Medicine
[13] Taichung Veterans General Hospital,Division of Hematology
[14] Buddhist Tzu-Chi General Hospital Taipei Branch,Oncology, Department of Internal Medicine
[15] Chang Gung Memorial Hospital-Keelung,Division of Hematology
[16] Kaohsiung Medical University,Oncology, Department of Internal Medicine
[17] College of Medicine,Department of Internal Medicine
[18] Kaohsiung Medical University,Hematology and Medical Oncology
[19] Koo Foundation Sun Yat-Sen Cancer Center,Division of Hematology/Oncology, Department of Medicine
[20] Taipei Veterans General Hospital,Division of Hematology
[21] National Yang-Ming University School of Medicine,Oncology, Department of Internal Medicine
[22] Chang Gung Memorial Hospital-Linkou,undefined
来源
关键词
Guidelines; Taiwan; MDS; ICT; Iron overload; Ferritin;
D O I
暂无
中图分类号
学科分类号
摘要
Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.
引用
收藏
页码:7 / 15
页数:8
相关论文
共 50 条
  • [31] Iron overload-induced genetic instability in myelodysplastic syndromes
    Westhofen, G.
    Ganster, C.
    Al-Ali, H. K.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 248 - 249
  • [32] RETROSPECTIVE EVALUATION OF IRON OVERLOAD PREVALENCE IN MYELODYSPLASTIC SYNDROMES AT THE DIAGNOSIS
    Ricerca, B. M.
    Voso, M. T.
    Greco, M.
    Fianchi, L.
    Pagano, L.
    Giordano, G.
    Piano, S.
    Storti, S.
    Leone, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 532 - 532
  • [33] Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes Recent Developments
    Leitch, Heather A.
    DRUGS, 2011, 71 (02) : 155 - 177
  • [34] Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes
    Wimazal, F.
    Noesslinger, T.
    Baumgartner, C.
    Sperr, W. R.
    Pfeilstoecker, M.
    Valent, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (05) : 406 - 411
  • [35] Treating myelodysplastic syndromes
    Ryan, C
    McCann, S
    IDRUGS, 2005, 8 (04) : 320 - 326
  • [36] Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
    Gattermann, N.
    LEUKEMIA RESEARCH, 2007, 31 : S15 - S16
  • [37] Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US A Literature Review
    Zhang, Bin
    Donga, Prina Z.
    Corral, Mitra
    Sasane, Medha
    Miller, Jeffrey D.
    Pashos, Chris L.
    PHARMACOECONOMICS, 2011, 29 (06) : 461 - 474
  • [38] Mortality burden of transfusion dependency and iron overload in patients with myelodysplastic syndromes
    Arnan, M.
    Pomares, H.
    Esteban, L.
    Alonso, E.
    Pareja, L.
    Sanchez-Ortega, I.
    Fernandez de Sevilla, A.
    Ribes, J.
    Duarte, R. F.
    LEUKEMIA RESEARCH, 2013, 37 : S140 - S140
  • [39] Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes
    González, FA
    Arrizabalaga, B
    Villegas, A
    Alonso, D
    Castro, M
    Remacha, A
    del Arco, A
    Núñez, GM
    MEDICINA CLINICA, 2005, 124 (17): : 645 - 647
  • [40] Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
    Roy, Noemi B. A.
    Myerson, Saul
    Schuh, Anna H.
    Bignell, Patricia
    Patel, Roger
    Wainscoat, Jim S.
    McGowan, Simon
    Marchi, Emanuele
    Atoyebi, Wale
    Littlewood, Tim
    Chacko, Joseph
    Vyas, Paresh
    Killick, Sally B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (04) : 521 - 524